To assess effect of Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC patients
Latest Information Update: 08 Jul 2021
Price :
$35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 09 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress